{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:10:50Z","timestamp":1790935850403,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01373-7","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:37:41Z","timestamp":1742009861000},"page":"919-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05139836","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schadeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Weyergraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusch","family":"Mortazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Abousamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"10247","key":"1373_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"6","key":"1373_CR2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"12","key":"1373_CR3","first-page":"133","volume":"6","author":"CH Na","year":"2019","unstructured":"Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12):133.","journal-title":"Children (Basel)"},{"issue":"8","key":"1373_CR4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","volume":"154","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903\u201312.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1373_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89(3):519\u201328.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1373_CR6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/1346-8138.15817","volume":"48","author":"YR Woo","year":"2021","unstructured":"Woo YR, Han Y, Lee JH, et al. Real-world prevalence and burden of genital eczema in atopic dermatitis: a multicenter questionnaire-based study. J Dermatol. 2021;48(5):625\u201332.","journal-title":"J Dermatol"},{"issue":"2","key":"1373_CR7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jdv.19500","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"1373_CR8","doi-asserted-by":"crossref","first-page":"ljac140.022","DOI":"10.1093\/bjd\/ljac140.022","volume":"188","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. 327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. Br J Dermatol. 2023;188(Suppl 2):ljac140.022.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1373_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jdv.19465","volume":"38","author":"A Heratizadeh","year":"2024","unstructured":"Heratizadeh A, Mempel M, von Kiedrowski R, et al. Checklist identification of candidates for systemic therapy in adult patients with atopic dermatitis in Germany: a multicentre study. J Eur Acad Dermatol Venereol. 2024;38(1):157\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10290","key":"1373_CR10","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"10290","key":"1373_CR11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"9","key":"1373_CR12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1373_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Bunick CG, Hong HC-H, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week\u00a016 results of an open-label randomized efficacy assessor-blinded head-to-head phase\u00a0IIIb\/IV study (Level Up). Br J Dermatol. 2025;192(1):36\u201345.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1373_CR14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis\u00a0Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1373_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson E, Eckert L, Gadkari A, et al. Validation of the atopic dermatitis control tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.","journal-title":"BMC Dermatol"},{"issue":"2","key":"1373_CR16","first-page":"307","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel T, Heratizadeh A, Aberer W, et al. S3 guideline atopic dermatitis: part 2\u2014systemic treatment. J Dtsch Dermatol Ges. 2024;22(2):307\u201320.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"1373_CR17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000519361","volume":"238","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Di Nardo L, et al. Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients. Dermatology. 2022;238(4):717\u201324.","journal-title":"Dermatology"},{"issue":"5","key":"1373_CR18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ced\/llad040","volume":"48","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Antonelli F, Peris K, Chiricozzi A. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment. Clin Exp Dermatol. 2023;48(5):558\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1373_CR19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81(4):943\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1373_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2340\/00015555-2480","volume":"97","author":"LB von Kobyletzki","year":"2017","unstructured":"von Kobyletzki LB, Thomas KS, Schmitt J, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol. 2017;97(1):86\u201390.","journal-title":"Acta Derm Venereol"},{"key":"1373_CR21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5414\/ALX02262E","volume":"5","author":"D Siegels","year":"2021","unstructured":"Siegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5:274\u201386.","journal-title":"Allergol Select"},{"issue":"4","key":"1373_CR22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.anai.2019.07.008","volume":"123","author":"W Wei","year":"2019","unstructured":"Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381-8.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1373_CR23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13555-023-01061-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Lockshin B, Lee LW, Chen Z, Daoud M, Korotzer A. Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year interim data from the PROSE Registry. Dermatol Ther (Heidelb). 2024;14(1):261\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1373_CR24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104\u00a0weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1373_CR25","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s12325-023-02490-5","volume":"40","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Adv Ther. 2023;40(5):2509\u201314.","journal-title":"Adv Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01373-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:17:36Z","timestamp":1743866256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01373-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stephan Weidinger received institutional research grants from LEO Pharma, Pfizer, and Sanofi Deutschland GmbH and lecture and\/or consultancy fees from AbbVie, Almirall, Boehringer, Eli Lilly, Galderma, GSK, LEO Pharma, Pfizer, Regeneron, and Sanofi. He is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Tobias Schadeck participated in noninterventional trials for AbbVie. Felix Jacobs\u00a0is a member of advisory boards and\/or a speaker for\u00a0AbbVie,\u00a0Alliance Pharma,\u00a0Almirall,\u00a0Hermal,\u00a0Janssen, Lilly, and Novartis. Ansgar Weyergraf served as a speaker, advisor, and\/or researcher for AbbVie, Almirall, Amgen, Arctic Bioscience, Biogen, Bristol-Myers-Squibb, Celgene, Hermal, Janssen, LEO, Lilly, Novartis, Pfizer, Sanofi, and UCB. Dariusch Mortazawi was an advisor, received honoraria and grants, and\/or participated in clinical trials for AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen-Cilag, LEO Pharma, Moberg Pharma, Novartis, Pfizer, Sandoz, Sanofi Genzyme, UCB Pharma, and Viatris. Tobias Hagemann is a member of advisory boards and\/or a speaker for AbbVie, Almirall Hermal, Bencard Allergie GmbH, Pierre Fabre Dermatologie, Regeneron, and Sanofi-Aventis. Fatima Abousamra, Thomas Mosch, and Bjoern Fritz are employees of AbbVie and may own AbbVie stock. Felix Lauffer is a\u00a0member of advisory boards and\/or a speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Myers-Squibb, Janssen, LEO Pharma, Lilly, Novartis, Roche, Sanofi, UCB, and Union Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"According to the requirements for non-interventional, observational studies, no additional diagnostic or monitoring procedures or measurements that would not be feasible for use in routine clinical care were done in this study. Study-related monitoring, if applicable, was permitted by the study sites\/investigators, including audits, independent ethics committee or independent review board review, and regulatory inspection(s). Ethics committee approval was obtained by the medical faculty in Kiel, Germany, on November 1, 2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}